[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644052":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":19,"collaborators":11,"id":21,"slug":11,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":25,"acronym":11,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":11,"enrollmentInfo":29,"targetDuration":11,"studyType":32,"phases":33,"briefSummary":35,"conditions":36,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":11},{"fullName":5,"class":6},"BrightPath Biotherapeutics Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BP2202","EXPERIMENTAL",null,[13],"Biological: BP2202",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Intravenous infusion",[9],{"type":20,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100644052",false,"NCT07667868","A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed\u002FRefractory Multiple Myeloma","A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Diagnosis of Multiple Myeloma with relapsed or refractory disease.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Adequate organ function.\n* Have measurable disease\n\nExclusion Criteria:\n\n* Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.\n* Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.","ALL","18 Years",{"count":30,"type":31},18,"ESTIMATED","INTERVENTIONAL",[34],"PHASE1","The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed\u002FRefractory Multiple Myeloma.",[37],"Relapsed\u002FRefractory Multiple Myeloma (RRMM)","NOT_YET_RECRUITING","2026-06-29",{"date":41,"type":42},"2026-07-01","ACTUAL",{"date":44,"type":31},"2026-10-01",{"date":46,"type":31},"2028-12-31",{"name":5,"class":6}]